Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?Christoph Röllig, Martin Bornhäuser, Stefan W. Krause et al.|Blood|2020Cited by 137
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patientsChristoph Röllig, Ulrich S. Schuler, Michael Krämer et al.|Annals of Oncology|2018Cited by 37
Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid LeukemiaChristoph Röllig, Martin Bornhäuser, Michael Krämer et al.|Blood|2019Cited by 18
Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ TrialChristoph Röllig, Ulrich S. Schuler, Michael Krämer et al.|Blood|2015Cited by 4